Aliases & Classifications for Orbital Disease

MalaCards integrated aliases for Orbital Disease:

Name: Orbital Disease 12 15
Orbital Diseases 44
Orbit 73

Classifications:



External Ids:

Disease Ontology 12 DOID:930
ICD10 33 H05 H05.9
ICD9CM 35 376 376.9
MeSH 44 D009916
UMLS 73 C0029182

Summaries for Orbital Disease

Disease Ontology : 12 An adnexa disease that is located in the eye socket.

MalaCards based summary : Orbital Disease, also known as orbital diseases, is related to exophthalmos and acute orbital inflammation, and has symptoms including eye manifestations and visual disturbance. An important gene associated with Orbital Disease is RHNO1 (RAD9-HUS1-RAD1 Interacting Nuclear Orphan 1). The drugs Hyaluronic acid and Propylthiouracil have been mentioned in the context of this disorder. Affiliated tissues include the eye socket, thyroid and eye.

Related Diseases for Orbital Disease

Diseases related to Orbital Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 25)
# Related Disease Score Top Affiliating Genes
1 exophthalmos 29.5 RHNO1 TSHR
2 acute orbital inflammation 10.4 PGBD1 RHNO1
3 orbital cellulitis 10.4 PGBD1 RHNO1
4 intracranial sinus thrombosis 10.4 PGBD1 RHNO1
5 cavernous sinus thrombosis 10.4 PGBD1 RHNO1
6 cranial nerve palsy 10.2 CHN1 RHNO1
7 amblyopia 10.1 CHN1 TFAP2A
8 esotropia 9.9 CHN1 TFAP2A
9 exotropia 9.8 CHN1 TNNI3K
10 congenital ptosis 9.8 CHN1 TNNI3K
11 thyroiditis 9.7
12 lymphoma 9.6
13 histiocytosis 9.6
14 herpes zoster 9.6
15 herpes zoster ophthalmicus 9.6
16 tukel syndrome 9.5 CHN1 TNNI3K
17 aging 9.4
18 langerhans cell histiocytosis 9.4
19 nodal marginal zone lymphoma 9.4
20 mastitis 9.4
21 graves' disease 9.4
22 rhabdomyosarcoma 9.4
23 hyperthyroidism 9.4
24 ocular motility disease 9.2 CHN1 TNNI3K
25 enophthalmos 7.6 CHN1 EPB41L1 FAF2 SASS6 TFAP2A TNNI3K

Graphical network of the top 20 diseases related to Orbital Disease:



Diseases related to Orbital Disease

Symptoms & Phenotypes for Orbital Disease

UMLS symptoms related to Orbital Disease:


eye manifestations, visual disturbance

Drugs & Therapeutics for Orbital Disease

Drugs for Orbital Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 180)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hyaluronic acid Approved, Vet_approved Phase 4,Not Applicable 9004-61-9 53477741
2
Propylthiouracil Approved, Investigational Phase 4,Phase 3,Phase 2 51-52-5 657298
3
Acetylcholine Approved Phase 4,Phase 2,Phase 3 51-84-3 187
4
Iodine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 7553-56-2 807
5
Triamcinolone Approved, Vet_approved Phase 4,Not Applicable 124-94-7 31307
6
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 50-24-8 5755
7
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 83-43-2 6741
8
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 53-03-2 5865
9
rituximab Approved Phase 4,Phase 2,Phase 3,Phase 1 174722-31-7 10201696
10
Ephedrine Approved Phase 4 299-42-3 9294
11
Pseudoephedrine Approved Phase 4 90-82-4 7028
12
Methotrexate Approved Phase 4,Not Applicable 1959-05-2, 59-05-2 126941
13
Diclofenac Approved, Vet_approved Phase 4,Phase 3 15307-86-5 3033
14
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 1 50-02-2 5743
15
Propranolol Approved, Investigational Phase 4,Phase 3,Not Applicable 525-66-6 4946
16
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
17
Bimatoprost Approved, Investigational Phase 4,Phase 3 155206-00-1 5311027
18
Dinoprost Tromethamine Approved, Vet_approved Phase 4 38562-01-5 5282415
19
leucovorin Approved, Nutraceutical Phase 4,Not Applicable 58-05-9 143 6006
20
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 59-30-3 6037
21
Dinoprost Investigational Phase 4 551-11-1 5283078
22 triamcinolone acetonide Phase 4,Not Applicable
23 cadexomer iodine Phase 4,Phase 3,Phase 2,Not Applicable
24 Prednisolone acetate Phase 4,Phase 2,Phase 3,Not Applicable
25 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
26 abobotulinumtoxinA Phase 4,Phase 2,Phase 3
27 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Not Applicable
28 Methylprednisolone acetate Phase 4,Phase 2,Phase 3,Not Applicable
29 Methylprednisolone Hemisuccinate Phase 4,Phase 2,Phase 3,Not Applicable
30 Adjuvants, Immunologic Phase 4,Not Applicable
31 Micronutrients Phase 4,Phase 3,Phase 2,Not Applicable
32 Cholinergic Agents Phase 4,Phase 2,Phase 3
33 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
34 Neuromuscular Agents Phase 4,Phase 2,Phase 3
35 Neuroprotective Agents Phase 4,Phase 2,Phase 3,Not Applicable
36 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Not Applicable
37 Anesthetics Phase 4,Phase 2,Phase 3,Not Applicable
38 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
39 Trace Elements Phase 4,Phase 3,Phase 2,Not Applicable
40 Anesthetics, Local Phase 4,Phase 2,Phase 3,Not Applicable
41 onabotulinumtoxinA Phase 4,Phase 2,Phase 3
42 Ophthalmic Solutions Phase 4,Phase 2
43 Triamcinolone diacetate Phase 4,Not Applicable
44 Triamcinolone hexacetonide Phase 4,Not Applicable
45 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
46 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
47 Viscosupplements Phase 4,Not Applicable
48 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
49 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2
50 Immunosuppressive Agents Phase 4,Not Applicable

Interventional clinical trials:

(show top 50) (show all 126)
# Name Status NCT ID Phase Drugs
1 A Prospective, Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy Unknown status NCT01969019 Phase 4 methylprednisolone, prednisone
2 Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease Unknown status NCT01738243 Phase 4 Hyaluronic Acid Gel injection;Saline injection
3 The Effect of Early Total Thyroidectomy in the Course of Graves' Orbitopathy Unknown status NCT01056419 Phase 4 Propylthiouracil
4 Adjuvant Treatment of Graves´ Ophthalmopathy With NSAID (aGO Study) Completed NCT01458600 Phase 4 Diclofenac;Methimazole;L-thyroxin;Propranolol;Metoprolol
5 Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease Completed NCT00946296 Phase 4 Potassium Iodide
6 Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study) Completed NCT02059655 Phase 4 Bimatoprost;Eye drop solution
7 Antithyroid Drugs During Radioiodine Therapy Completed NCT00150137 Phase 4 Methimazole
8 Block-replacement Therapy During Radioiodine Therapy Completed NCT00150124 Phase 4 MTZ+LT4;Methimazole
9 Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections Completed NCT01599273 Phase 4 subconjunctival triamcinolone injection
10 Prevention Relapse of Graves' Disease by Intrathyroid Injection of Dexamethasone Completed NCT00917241 Phase 4 MMI combined with IID;MMI
11 Is the Routine Pressure Dressing After Thyroidectomy Necessary? Completed NCT00400465 Phase 4
12 Using A Novel Classification System in Intravenous GCs Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial Recruiting NCT03107078 Phase 4 Glucocorticoids
13 Rituximab (RTX) Therapy in Patients With Active TAO Recruiting NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
14 A Trial to Evaluate the Efficacy of Orbital Radiotherapy in Graves' Orbitopathy Not yet recruiting NCT03098225 Phase 4 Methylprednisolone
15 Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease Not yet recruiting NCT02339142 Phase 4 intravenous corticosteroids (methylprednisolone)
16 Use of Botox in the Management of Thyroid Related Upper Eyelid Retraction Withdrawn NCT01272414 Phase 4 Botulinum Toxin Type A;Saline injection
17 The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients. Withdrawn NCT01927406 Phase 4 Prostaglandin Analog;Timolol
18 The Prospective Study of Standard Treatment of Graves Disease Iodine 131 and Prevention of Adverse Reactions Unknown status NCT01204359 Phase 3
19 Early Levothyroxine Post Radioactive Iodine Unknown status NCT01950260 Phase 2, Phase 3 Levothyroxine
20 Prednisone Versus Doxycycline in the Treatment of Graves' Orbitopathy Unknown status NCT01809444 Phase 2, Phase 3 Prednisone+placebo of Doxycycline;Doxycycline+placebo of Prednisone
21 Effect of Percutaneous Botulinum Toxin A Injection on Natural Course of Upper Lid Retraction in Thyroid Eye Disease Unknown status NCT00370734 Phase 2, Phase 3 Botulinum toxin A injection
22 Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyroïdism on Quality of Life, Efficiency and Tolerance Completed NCT01295333 Phase 3 the early prophylactic introduction of low dose of LT4 (50 µg/d) at 15 days post-ablation;The initiation of LT4 as soon as the first biological signs of hypothyroidism.
23 Comparison of Different Doses of 131I in Severe Graves' Hyperthyroidism Completed NCT01039818 Phase 3
24 Treatment of Soft Tissue Expansion in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues Completed NCT02155049 Phase 3 bimatoprost 0.03%
25 Tocilizumab Treatment in Graves´ Ophthalmopathy (Graves´ Orbitopathy or Thyroid Eye Disease) Completed NCT01297699 Phase 3 Tocilizumab (RoActemra®);Sterile 0.9% Sodium Chloride
26 Trial of Rituximab for Graves' Ophthalmopathy Completed NCT00595335 Phase 2, Phase 3 Rituximab;Saline;Methylprednisolone
27 The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy Recruiting NCT01579539 Phase 3 Methylprednisolone;Esomeprazole
28 Efficacy and Safety of Cholestyramine and Prednisolone as Adjunctive Therapy in Treatment of Overt Hyperthyroidism Recruiting NCT03303053 Phase 3 Cholestyramine Powder 4g;Prednisolone;Standard treatment
29 Total Thyroidectomy Versus Thionamides in Patients With Moderate-to-Severe Graves' Ophthalmopathy Recruiting NCT03066076 Phase 3 Antithyroid Drug
30 Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study Recruiting NCT03298867 Phase 3
31 Treatment of Graves´Ophthalmopathy With Diclofenac or Simvastatin (GO-DS) Recruiting NCT03131726 Phase 3 Simvastatin 40mg;Diclofenac Potassium 50 MG
32 Bupivacaine Injection of Eye Muscles to Treat Strabismus Recruiting NCT01616108 Phase 2, Phase 3 Bupivacaine
33 Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study Enrolling by invitation NCT03461211 Phase 3
34 The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease Not yet recruiting NCT02422368 Phase 2, Phase 3 Methylprednisolone + ASTED;Methylprednisolone +Placebo
35 The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease (TED) Not yet recruiting NCT02393183 Phase 2, Phase 3 ASTED
36 Doxycycline Treatment in Mild Graves' Orbitopathy Unknown status NCT02203682 Phase 2 Doxycycline;placebo
37 Role of the Microbiome in Graves' Orbitopathy Unknown status NCT02373995 Phase 1, Phase 2
38 Polycaprolactone / Tricalcium Phosphate (PCL/TCP) v Titanium Orbital Implant : Randomised Trial Unknown status NCT01119144 Phase 2
39 Rituximab in the Treatment of Scleritis and Non-Infectious Orbital Inflammation Completed NCT00415506 Phase 1, Phase 2 Rituximab
40 Pilot Study to Determine Safety and Efficacy of Orbital Injections of LIPO-102 in Patients With Symptomatic Exophthalmos Associated With Thyroid-related Eye Disease (TED) Completed NCT00954057 Phase 2 LIPO-102;Placebo
41 Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy Completed NCT01727973 Phase 1, Phase 2 Doxycycline
42 Effects Of Oral Alfacalcidol On Maturation Of Dendritic Cells In Graves' Disease Patients Completed NCT02993302 Phase 2 1α-D3;Placebos
43 A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease Completed NCT02713256 Phase 2 CFZ533
44 Radioactive Iodide Therapy for Pediatric Graves' Disease Completed NCT01269749 Phase 2 ATD Group
45 Rituximab in the Treatment of Graves' Disease Completed NCT00150111 Phase 1, Phase 2 Methimazole;Rituximab
46 rhTSH, Thyroid Size, and Radioiodine Therapy in Benign Goiter Completed NCT00145366 Phase 2 Recombinant human thyrotropin (Thyrogen)
47 Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease Completed NCT01868997 Phase 2 teprotumumab;normal saline
48 Rituximab Treatment of Graves' Dysthyroid Ophthalmopathy Completed NCT00424151 Phase 1, Phase 2 Rituximab
49 Celecoxib for Thyroid Eye Disease Recruiting NCT02845336 Phase 2 Celecoxib;artificial tears
50 Effects of Atorvastatin in Graves' Orbitopathy (GO) Not yet recruiting NCT03110848 Phase 2 Atorvastatin;Methylprednisolone

Search NIH Clinical Center for Orbital Disease

Cochrane evidence based reviews: orbital diseases

Genetic Tests for Orbital Disease

Anatomical Context for Orbital Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Orbital Disease:

19
The Eye Socket

MalaCards organs/tissues related to Orbital Disease:

41
Thyroid, Eye, B Cells, Bone, T Cells, Testes

Publications for Orbital Disease

Articles related to Orbital Disease:

(show top 50) (show all 100)
# Title Authors Year
1
IgG4-related orbital disease. ( 29866378 )
2018
2
Treatment of Pediatric IgG4-Related Orbital Disease With TNF-I+ Inhibitor. ( 28700400 )
2017
3
IgG4-related orbital disease masquerading as thyroid eye disease, vice versa, or both? ( 29053038 )
2017
4
Incipient Ocular Mucosa-associated Lymphoid Tissue Lymphoma in IgG4-related Orbital Disease. ( 28367047 )
2017
5
Immunoglobulin G4-related orbital disease: An important differential diagnosis for orbital swellings with lymphoplasmacytic infiltration. ( 28937398 )
2017
6
Orbital Disease in Neuro-Ophthalmology. ( 27886890 )
2017
7
Infliximab for IgG4-Related Orbital Disease. ( 26784550 )
2016
8
IgG4 related orbital disease presenting with unilateral eyelid swelling. ( 27565007 )
2016
9
IgG4-related orbital disease mass lesion. ( 27085284 )
2016
10
Characteristics, diagnosis and therapeutic strategies for IgG4-related orbital disease. ( 27116895 )
2016
11
A case of non-lacrimal immunoglobulin G4 (IgG4)-related orbital disease with mastitis. ( 26700191 )
2016
12
IgG4-related Orbital Disease and Its Mimics in a Western Population. ( 26379149 )
2015
13
Langerhans cell histiocytosis with presentation as orbital disease. ( 26167225 )
2015
14
Immunoglobulin G4-related orbital disease: report of two pediatric cases. ( 25897575 )
2015
15
Rituximab for the treatment of IgG4-related orbital disease: experience from five cases. ( 25341435 )
2014
16
Sequential biopsies from immunoglobulin G4-related orbital disease demonstrate progressive fibrosis. ( 24617918 )
2014
17
Kimura's disease of the lacrimal gland mimicking IgG4-related orbital disease. ( 25511019 )
2014
18
The meaning of diagnoses in orbital disease. ( 24022349 )
2013
19
Bilateral orbital and optic nerve endoscopic endonasal decompression for nonspecific inflammatory orbital disease: case report. ( 23042140 )
2013
20
Teaching neuroimages: IgG4-related orbital disease and enlargement of the trigeminal nerve branches. ( 24101754 )
2013
21
IgG4-related orbital disease: a meta-analysis and review. ( 22963447 )
2013
22
MAGNETIC RESONANCE IMAGING CONTRAST ENHANCEMENT OF EXTRA-OCULAR MUSCLES IN DOGS WITH NO CLINICAL EVIDENCE OF ORBITAL DISEASE. ( 23890158 )
2013
23
The usefulness of infraorbital nerve enlargement on MRI imaging in clinical diagnosis of IgG4-related orbital disease. ( 22644450 )
2012
24
Addition of a minimally invasive medial orbital approach in the endoscopic management of advanced sino-orbital disease: cadaver study with clinical correlations. ( 21271602 )
2011
25
Neuro-ophthalmology of orbital disease. ( 21601077 )
2011
26
Ophthalmic complications following treatment of paranasal sinus rhabdomyosarcoma in comparison to orbital disease. ( 21242849 )
2011
27
Zolendronate associated inflammatory orbital disease. ( 20930911 )
2010
28
Spectrum of orbital disease in South India: an aravind study of 6328 consecutive patients. ( 20592641 )
2010
29
Image-guided transnasal endoscopic techniques in the management of orbital disease. ( 20807018 )
2010
30
Orbital disease in neuro-ophthalmology. ( 20637996 )
2010
31
Imaging for neuro-ophthalmic and orbital disease - a review. ( 19016810 )
2009
32
Intraocular pressure change in orbital disease. ( 19682621 )
2009
33
Bilateral infiltrative orbital disease: is it chemically induced? ( 18982043 )
2008
34
Isolated upper eyelid retraction: a sign of idiopathic inflammatory orbital disease. ( 18209649 )
2008
35
Hyperthyroidism and severity of orbital disease do not change the central corneal thickness in Graves' ophthalmopathy. ( 18203097 )
2008
36
Severe, permanent orbital disease in herpes zoster ophthalmicus. ( 18716975 )
2008
37
Assessment of ultrasonography and computed tomography for the evaluation of unilateral orbital disease in dogs. ( 17331049 )
2007
38
A personal view: probability in medicine, levels of (Un)certainty, and the diagnosis of orbital disease (with particular reference to orbital "pseudotumor"). ( 18071128 )
2007
39
Radiologic evaluation of lacrimal and orbital disease. ( 16982252 )
2006
40
Office evaluation of lacrimal and orbital disease. ( 16982254 )
2006
41
Orbital socket contracture: a complication of inflammatory orbital disease in patients with Wegener's granulomatosis. ( 15774931 )
2005
42
Imaging for neuro-ophthalmic and orbital disease. ( 15531324 )
2004
43
Epidemiology of orbital disease. ( 12867378 )
2003
44
MRI artifact masquerading as orbital disease. ( 14750572 )
2001
45
Sporadic Burkitt's lymphoma presenting as solely orbital disease in a 78-year-old. ( 11318275 )
2001
46
Use of magnetic resonance imaging for the investigation of orbital disease in small animals. ( 10812543 )
2000
47
Frequency-selective fat suppression MR imaging. Localized asymmetric failure of fat suppression mimicking orbital disease. ( 9093955 )
1997
48
Orbital disease, optic nerve and chiasm. ( 9099523 )
1997
49
Electron/photon matched field technique for treatment of orbital disease. ( 9069323 )
1997
50
The approach to orbital disease in the dog and cat. ( 22047442 )
1997

Variations for Orbital Disease

Expression for Orbital Disease

Search GEO for disease gene expression data for Orbital Disease.

Pathways for Orbital Disease

GO Terms for Orbital Disease

Biological processes related to Orbital Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of cardiac conduction GO:1903779 8.62 CASQ1 TNNI3K

Molecular functions related to Orbital Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.32 CASQ1 CHN1 EPB41L1 FAF2 PGBD1 RHNO1

Sources for Orbital Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....